Cas:444167-02-6 2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole manufacturer & supplier

Chemical Name:2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole

CAS.NO:444167-02-6

Synonyms:2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole

Molecular Formula:C₁₁H₁₄N₂O

Molecular Weight:190.24200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:27.05000

Exact Mass:190.11100

LogP:2.14430

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole Use and application,2-Ethyl-5-methoxy-1-methyl-1H-benzimidazole technical grade,usp/ep/jp grade.

Related News: During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. (E)-2-(3-(3-(13,24,33,43,53,63-hexaoxin-2-yl)-24,34,43,53-pentaoxol-2-yl)-24,34-tetraoxidan-2-enyl)-13,24,33,43,53,63-hexaoxine manufacturers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. RNA (human immunodeficiency virus 1 strain LP31 country Spain genepol fragment) suppliers One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. Schwefligsaeure-(1,1-dimethyl-2,2-diphenyl-ethylenester) vendor & factory The FDA has already clashed with COVID vaccine heavyweights Pfizer and BioNTech over the immediate need for boosters for the broader population. While the drugmakers argue a third shot would offer the highest level of protection, both the CDC and FDA immediately came out against that assertion.,CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication.